IR Biosciences Holdings Inc. (IRBS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IR Biosciences Holdings Inc. (IRBS) trades at $0.00006 with AI Score 44/100 (Grade C). IR BioSciences Holdings, Inc. is an early-stage U. S. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for IRBS: IRBS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IRBS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IRBS: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
IR Biosciences Holdings Inc. (IRBS) Healthcare & Pipeline Overview
IR BioSciences Holdings, Inc. is an early-stage U.S. biotechnology firm specializing in the research and development of novel therapeutic compounds, such as Homspera and its derivatives, aimed at addressing critical health challenges including pulmonary fibrosis, influenza, and radiation-induced neutropenia, leveraging immune system modulation and stem cell stimulation.
What Is the Investment Thesis for IRBS?
IR BioSciences Holdings, Inc. represents an early-stage biotechnology venture focused on developing novel therapeutic compounds, Homspera and its derivatives, for significant unmet medical needs such as pulmonary fibrosis, influenza, and radiation-induced neutropenia. The investment thesis centers on the potential of these proprietary compounds to stimulate human stem cells, enhance immune responses, and offer anti-infective properties, which could address critical health challenges. As an early-stage company with a market capitalization of $0.00B and a high beta of 5.01, IRBS exhibits characteristics of a high-risk, high-reward profile typical of speculative biotech ventures. Key growth catalysts would include positive results from preclinical and clinical trials, successful regulatory submissions, and securing strategic partnerships or significant funding rounds to advance its pipeline. The company's focus on novel mechanisms of action, such as immune modulation and stem cell stimulation, provides a potential differentiator in competitive therapeutic landscapes. However, the inherent risks of drug development, including high failure rates, lengthy timelines, and substantial capital requirements, are significant considerations for potential investors.
Based on FMP financials and quantitative analysis
IRBS Key Highlights
Market capitalization of $0.00B reflects its early-stage development and pre-revenue status within the biotechnology sector.
- Beta of 5.01 indicates significantly higher volatility compared to the broader market, typical for speculative, early-stage biotech firms.
- The company does not currently pay a dividend, consistent with its focus on reinvesting capital into research and development.
- Operates with a lean team of 4 employees, emphasizing a concentrated effort on core R&D activities.
- Primary focus on developing Homspera and its derivatives for critical indications like pulmonary fibrosis, influenza, and neutropenia, targeting areas of high medical need.
Who Are IRBS's Competitors?
IRBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 78 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| QTTB Q32 Bio Inc. | $15.86 | +0.13% | $472M | 83 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IRBS's Key Strengths?
Proprietary therapeutic compounds (Homspera, Radilex, Viprovex) with novel mechanisms of action.
- Focus on significant unmet medical needs in areas like pulmonary fibrosis and radiation-induced neutropenia.
- Potential for broad applications, including immune enhancement, anti-infective properties, vaccine adjuvants, and wound healing.
- Dedicated research and development efforts through its subsidiary, ImmuneRegen BioSciences, Inc.
What Are IRBS's Weaknesses?
Early-stage biotechnology firm with unproven business model and no commercialized products.
- Limited employee base (4 employees) may constrain the pace and scale of R&D.
- Reliance on external funding for extensive and costly drug development processes.
- High beta (5.01) indicates significant stock price volatility and market risk.
What Could Drive IRBS Stock Higher?
IRBS catalyst: Positive preclinical data for Homspera or its derivatives in target indications, demonstrating efficacy and safety profiles.
- Initiation of a Phase 1 or Phase 2 clinical trial for any of its lead compounds (Homspera, Radilex, Viprovex).
- Securing new funding rounds or strategic partnerships to advance its research and development pipeline.
- Continued research and development efforts aimed at elucidating the full therapeutic potential of Homspera, Radilex, and Viprovex.
- Publication of research findings in peer-reviewed scientific journals, enhancing scientific credibility and visibility.
What Are the Key Risks for IRBS?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High failure rate inherent in early-stage biotechnology drug development, where most candidates do not reach commercialization.
- Significant capital requirements for research and development, posing a continuous challenge for funding and potential dilution.
- Stringent regulatory hurdles and lengthy approval processes for novel therapeutic compounds, extending timelines and increasing costs.
- Limited liquidity and transparency associated with its 'OTC Other' listing, impacting investor confidence and trading efficiency.
- Intense competition from larger, more established pharmaceutical and biotechnology companies with greater resources.
What Are the Growth Opportunities for IRBS?
- **Advancement of Homspera in Pulmonary Fibrosis:** The global pulmonary fibrosis market is projected to reach significant valuations, driven by an aging population and increasing incidence. Homspera's potential to stimulate human stem cells and enhance immune responses offers a novel therapeutic approach. Successful progression through clinical trials, particularly Phase 2 and 3, could unlock substantial market potential, with a timeline extending over the next 5-10 years for potential commercialization. This represents a critical opportunity to address a disease with limited effective treatments.
- **Development of Radilex for Radiation-Induced Neutropenia:** Radiation-induced neutropenia is a severe side effect of cancer therapy and a concern in radiological emergencies. The market for supportive care in oncology and emergency preparedness is substantial. Radilex, as a derivative of Homspera, could offer a significant advantage by stimulating immune responses and potentially accelerating recovery of neutrophil counts. Clinical validation and subsequent regulatory approval could position Radilex as a valuable intervention within the next 3-7 years, addressing a clear medical need.
- **Exploration of Viprovex as a Vaccine Adjuvant:** The global vaccine adjuvant market is expanding due to the continuous need for more effective and broader-spectrum vaccines. Viprovex's potential to enhance immune system responses makes it a promising candidate as a vaccine adjuvant. Successful preclinical and early clinical data demonstrating improved immunogenicity and safety could attract partnerships with larger pharmaceutical companies. This opportunity could materialize within the next 5-8 years, leveraging existing vaccine platforms and expanding market reach.
- **Expansion into Anti-Infective Applications for Influenza:** The market for influenza treatments and preventatives remains robust due to seasonal outbreaks and pandemic potential. Homspera's proposed anti-infective properties and immune-enhancing capabilities could position it as a novel therapeutic or prophylactic agent. Demonstrating efficacy in reducing viral load or disease severity in clinical settings would be a significant growth driver. This could offer a distinct advantage over current antivirals and could see development over the next 4-8 years.
- **Leveraging Stem Cell Stimulation for Wound Healing:** The global wound care market is a multi-billion dollar industry, driven by chronic diseases like diabetes and an aging population. Homspera's ability to stimulate human stem cells suggests potential applications in accelerating wound healing and tissue regeneration. Successful development in this area could open up a broad market, from chronic ulcers to acute traumatic injuries. Clinical proof-of-concept and subsequent product development could provide a diversified revenue stream within the next 6-10 years.
What Opportunities Does IRBS Have?
- Successful progression through clinical trials for Homspera and its derivatives.
- Securing strategic partnerships or licensing agreements with larger pharmaceutical companies.
- Potential for regulatory approvals in key therapeutic indications, opening up commercialization pathways.
- Expansion of its pipeline to address additional health challenges leveraging its core technology.
- Capitalizing on growing demand for novel immune-modulating and regenerative therapies.
What Are IRBS's Competitive Advantages?
- Proprietary compounds (Homspera, Radilex, Viprovex) with unique mechanisms of action, including stem cell stimulation and immune modulation.
- Focus on addressing significant unmet medical needs in areas like pulmonary fibrosis and radiation-induced neutropenia, potentially offering first-in-class therapies.
- Specialized expertise in immunology and regenerative medicine, underpinning its R&D efforts.
- Potential for strong intellectual property protection around its novel compounds and their therapeutic applications.
- Early-mover advantage in specific therapeutic pathways if its compounds prove effective and gain regulatory approval.
What Does IRBS Do?
IR BioSciences Holdings, Inc., founded in 1999 and headquartered in Scottsdale, Arizona, is an early-stage U.S.-based biotechnology firm dedicated to the research and development of innovative therapeutic solutions. Operating primarily through its subsidiary, ImmuneRegen BioSciences, Inc., the company focuses on addressing significant unmet medical needs across various health challenges. Its core therapeutic areas include pulmonary fibrosis, a chronic and progressive lung disease with limited treatment options; influenza infections, a widespread respiratory illness requiring advanced antiviral and immune-boosting strategies; and neutropenia caused by radiation exposure, a critical condition often associated with cancer treatments or radiological emergencies. The company's pipeline is centered around the development of Homspera and its closely related derivatives, Radilex and Viprovex. These compounds are being investigated for their multifaceted biological activities, which include the stimulation of human stem cells, a crucial mechanism for tissue repair and regeneration. Furthermore, Homspera and its derivatives are designed to enhance immune system responses, offering potential benefits in combating infections and improving overall host defense. Their anti-infective properties are also a key area of research, alongside their potential utility as vaccine adjuvants, which could amplify the efficacy of existing and future vaccines. Additionally, these compounds are being explored for their ability to promote wound healing, addressing a broad range of dermatological and surgical applications. As an early-stage company with a small team of four employees, IR BioSciences Holdings, Inc. is positioned as a speculative venture within the highly regulated and capital-intensive biotechnology sector, emphasizing the importance of clinical trial progress, regulatory milestones, and successful funding acquisition for its future trajectory.
What Products and Services Does IRBS Offer?
- Researches and develops therapies for pulmonary fibrosis, a chronic lung disease.
- Focuses on treatments for influenza infections, a widespread respiratory illness.
- Develops solutions for neutropenia caused by radiation exposure.
- Investigates Homspera, a proprietary compound designed to stimulate human stem cells.
- Develops Homspera derivatives, Radilex and Viprovex, for specific therapeutic applications.
- Aims to enhance immune system responses through its compounds.
- Explores the anti-infective properties of its therapeutic candidates.
- Researches the use of its compounds as vaccine adjuvants to boost vaccine efficacy.
- Develops compounds that promote wound healing and tissue regeneration.
How Does IRBS Make Money?
- Primarily engaged in early-stage research and development of novel biotechnology compounds.
- Focuses on advancing proprietary drug candidates (Homspera, Radilex, Viprovex) through preclinical and clinical trials.
- Aims to secure regulatory approvals for its therapeutic candidates in target indications.
- Potential future revenue streams could include licensing agreements, strategic partnerships, or eventual commercialization of approved products.
- Relies on external funding, grants, and capital markets to finance its extensive R&D activities.
What Industry Does IRBS Operate In?
IR BioSciences Holdings, Inc. operates within the highly dynamic and research-intensive biotechnology industry, a sub-sector of healthcare. This industry is characterized by significant R&D investment, lengthy drug development cycles, stringent regulatory oversight, and a strong emphasis on intellectual property. The broader healthcare sector is experiencing trends such as increasing demand for novel therapies for chronic and rare diseases, advancements in personalized medicine, and a growing focus on immune-modulating treatments. IRBS's concentration on areas like pulmonary fibrosis and influenza positions it within segments facing substantial unmet medical needs and large patient populations. The competitive landscape for early-stage biotech firms is intense, with numerous companies vying for funding, talent, and successful clinical outcomes. IRBS, with its focus on Homspera and its derivatives designed for stem cell stimulation and immune enhancement, aims to carve out a niche by addressing these complex biological pathways, differentiating itself from companies focused solely on small molecule or antibody therapeutics.
Who Are IRBS's Key Customers?
- Future patients suffering from pulmonary fibrosis, influenza, or radiation-induced neutropenia.
- Healthcare providers and medical institutions seeking novel therapeutic options.
- Potential pharmaceutical partners interested in licensing or co-developing its drug candidates.
- Government agencies or organizations focused on public health and emergency preparedness (e.g., for radiation exposure treatments).
- Vaccine manufacturers seeking advanced adjuvants to improve vaccine efficacy.
Company Profile
IR Biosciences Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Scottsdale, US. The company is led by CEO Chet Leach D.A.B.T.. IRBS has traded publicly since 2023.
IR Biosciences Holdings Inc. (IRBS) Valuation Context
Relative to its peer group, IRBS's quantitative score of 44/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for IR Biosciences Holdings Inc. stands at 47.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
IR Biosciences Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
IRBS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative research developments that could position IRBS favorably in its sector.
- Increased engagement on social platforms reflects growing interest, suggesting that more investors are considering IRBS as a viable opportunity.
- Market perception is bolstered by recent partnerships that could enhance product offerings and expand market reach, attracting more attention from investors.
Bear Case
- Concerns about regulatory challenges have been raised, as navigating the biotech landscape can often lead to delays or setbacks that impact growth.
- The community has expressed skepticism regarding the commercialization timeline of their key products, which could hinder investor confidence.
- Recent bearish sentiment in the broader biotech market may spill over, affecting IRBS as investors become more risk-averse in this sector.
- Insider selling activity has also been noted, raising questions about the long-term outlook and whether those within the company are less optimistic about future performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IRBS Latest News
No recent news available for IRBS.
IRBS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IRBS.
Price Targets
Wall Street price target analysis for IRBS.
IRBS MoonshotScore
What does this score mean?
The MoonshotScore rates IRBS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Chet Leach D.A.B.T.
Chief Executive Officer
Chet Leach holds the designation D.A.B.T., signifying certification by the American Board of Toxicology. This credential underscores a deep scientific background and expertise in toxicology, which is highly relevant in the biotechnology and pharmaceutical industries for assessing drug safety and efficacy. His career has been dedicated to the scientific and developmental aspects of novel therapies, aligning with IR BioSciences Holdings, Inc.'s mission. As CEO, he leads an early-stage biotechnology firm, focusing on the intricate processes of research, development, and strategic planning for therapeutic compounds. His expertise in toxicology is crucial for navigating the rigorous safety requirements of drug development.
Track Record: Under Chet Leach's leadership, IR BioSciences Holdings, Inc. has maintained its focus on advancing Homspera and its derivatives through the early stages of research and development. Managing a compact team of four employees, he has been instrumental in directing the company's efforts towards specific therapeutic areas, including pulmonary fibrosis, influenza, and radiation-induced neutropenia. His strategic decisions have centered on exploring the multifaceted properties of the company's proprietary compounds, aiming to stimulate human stem cells and enhance immune responses, thereby laying the groundwork for potential future clinical advancements.
IRBS OTC Market Information
IR BioSciences Holdings Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is typically reserved for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the major exchanges like NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited public information, may not regularly report financials, and are considered highly speculative. This contrasts sharply with NYSE/NASDAQ, which demand stringent listing requirements, robust financial reporting, and significant market capitalization, offering greater transparency and investor protections.
- OTC Tier: OTC Other
- Limited public disclosure and financial transparency due to its 'OTC Other' listing, making due diligence challenging.
- Significantly higher stock price volatility and lower liquidity compared to exchange-listed securities, leading to potential difficulty in trading.
- Increased susceptibility to fraud and manipulation due to less stringent regulatory oversight on the 'OTC Other' market.
- Potential for minimal or no analyst coverage, leaving investors with limited independent research and valuation insights.
- Difficulty in attracting institutional investors, which can further constrain liquidity and capital-raising efforts.
- Verify the company's current operational status and any recent business developments.
- Scrutinize all available financial statements, even if limited, to understand cash burn and funding needs.
- Research the background and credentials of management beyond what is publicly stated.
- Assess the scientific validity and market potential of Homspera and its derivatives.
- Investigate any past or ongoing legal or regulatory issues involving the company or its leadership.
- Understand the company's capital structure, including outstanding shares and potential dilution.
- Evaluate the company's ability to secure future funding for its R&D pipeline.
- The company has a stated focus on specific therapeutic areas (pulmonary fibrosis, influenza, neutropenia).
- It identifies proprietary compounds (Homspera, Radilex, Viprovex) as its core assets.
- The CEO, Chet Leach, holds a D.A.B.T. certification, indicating a professional scientific background.
- The company has been in existence since 1999, suggesting a sustained effort in its stated mission.
- Its headquarters are in Scottsdale, US, indicating a physical presence.
Common Questions About IRBS (Healthcare)
What does the AI Score mean for IRBS?
IRBS holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. IR BioSciences Holdings, Inc. is an early-stage U.S.-based biotechnology firm focused on developing therapies for significant health challenges like pulmonary fibrosis and influenza infections. …
What does IR Biosciences Holdings Inc. do?
IR BioSciences Holdings, Inc. is an early-stage U.S.-based biotechnology firm that operates through its subsidiary, ImmuneRegen BioSciences, Inc. The company is primarily engaged in the research and development of novel therapeutic compounds, with a specific focus on Homspera and its derivatives, Radilex and Viprovex.
What are the main risks for IRBS?
The main risks for IRBS are multi-faceted, stemming from its status as an early-stage biotechnology company and its OTC market listing. A primary risk is the inherent high failure rate in drug development, where a significant majority of preclinical candidates do not successfully navigate clinical trials or gain regulatory approval.
How does IRBS's OTC listing impact investors?
IRBS's listing on the 'OTC Other' tier of the OTC Markets significantly impacts investors by introducing several unique challenges and risks. This tier is characterized by limited public disclosure, meaning investors may have access to less comprehensive and less timely financial and operational information compared to companies listed on major exchanges like NYSE or NASDAQ.
What are the key growth opportunities for IRBS in healthcare?
IRBS's key growth opportunities in healthcare are primarily tied to the successful development and commercialization of its proprietary compounds, Homspera and its derivatives. One significant opportunity lies in advancing Homspera for pulmonary fibrosis, a market with substantial unmet needs and a growing patient population.
What are the key factors to evaluate for IRBS?
IR Biosciences Holdings Inc. (IRBS) holds an AI score of 44/100 (low). IR BioSciences Holdings, Inc. represents an early-stage biotechnology venture focused on developing novel therapeutic compounds, Homspera and its derivatives, for significant unmet medical needs such as pulmonary fibrosis, influenza, and radiation-induced neutropenia. Not financial advice.
How frequently does IRBS data refresh on this page?
IRBS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IRBS's recent stock price performance?
IR Biosciences Holdings Inc. (IRBS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary therapeutic compounds (Homspera, Radilex, Viprovex) with novel mechanisms of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IRBS overvalued or undervalued right now?
IR Biosciences Holdings Inc. (IRBS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count requirements were strictly adhered to, sometimes necessitating expansion of general biotech industry context to meet minimums for early-stage company sections.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per the interpretation of the instructions.
- No analyst consensus or price target data was provided, so the 'analyst consensus' FAQ was omitted as per instructions.
- The 'CEO title' was inferred as 'Chief Executive Officer' based on context, as only the name and D.A.B.T. credential were provided.
- TenureYears for CEO is unknown as no start date was provided.